Anne w Beaven, MD
Duke University · Duke University Medical Center Durham, NC USA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anne w Beaven, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:36 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02757248 · Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCLAnne Beaven, MD · withdrawn · PTCL, CTCL · principal investigator
- Ph2NCT01121757 · Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone LymphomaDuke University · terminated · Follicular Lymphoma, Marginal Zone Lymphoma · principal investigator
- Ph2NCT00978432 · Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Anne Beaven, MD · terminated · Diffuse Large B-cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.